[Skip to Content]
[Skip to Content Landing]
Article
July 19, 1952

ANTIBIOTICS IN TREATMENT OF PANCREATIC FIBROSIS, WITH EMPHASIS ON TERRAMYCIN

Author Affiliations

Boston
From the Children's Medical Center, Boston, Division of Laboratories and Research, and Department of Pediatrics, Harvard Medical School.; Assistant Professor of Pediatrics, Harvard Medical School, Chief, Division of Clinical Laboratories, Children's Hospital (Dr. Shwachman); House Officer, Division of Laboratories, Children's Hospital (Dr. Silverman); Instructor in Pediatrics, Harvard Medical School (Dr. Patterson); and Research Fellow, Division of Laboratories and Research, Children's Hospital (Dr. Zheutlin).

JAMA. 1952;149(12):1101-1108. doi:10.1001/jama.1952.02930290023006
Abstract

The beneficial effects of aureomycin in the management of patients with pancreatic fibrosis (mucoviscidosis) have been demonstrated.1 An extension of observations begun three years ago, and including over 100 patients, shows a favorable response in over 90%. Anticipation of the appearance of refractoriness to aureomycin and the poor response of the occasional patient to aureomycin suggested the use of terramycin.2 The present report is an evaluation of terramycin in the treatment of 49 patients with pancreatic fibrosis. All patients, with two exceptions (the patients in cases 2 and 3), had pulmonary infections of varying severity. A brief note concerning the efficacy of terramycin has been made.3 A full description of this disease is given elsewhere.4 The main clinical features drawing attention to this condition in early infancy are hunger, with failure to gain weight on an adequate caloric intake; the passage of large, foul, and frequent

First Page Preview View Large
First page PDF preview
First page PDF preview
×